Address: 823 Jays Drive
Lansdale, PA 19446,United States of America
Tel:
Web: http://www.jdptherapeutics.com/default.aspx
JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life-threatening diseases with significant unmet medical needs, primarily for use in acute care in a hospital setting.
Small Molecule Therapeutics
Michael Hogue, CEO of the American Pharmacists Association (APhA), shares his vision for the future of the pharmacy profession and its evolving role in healthcare. He discusses the strategic priorities…
Kendalle O’Connell, President and CEO of MassBio, shares how Massachusetts has built one of the world’s most dynamic life sciences hubs through a mix of bold public investment, targeted programmes,…
The latest stories from healthcare and the life sciences in the US. Vinay Prasad is reinstated as head of the FDA’s CBER following a brief resignation; HHS fires Gray Delany…
The latest stories from healthcare and the life sciences in the US. The FDA names Stanford’s George Tidmarsh as the new head of CDER; AstraZeneca commits USD 50 billion to…
What if ageing itself, not just individual diseases, was the root cause of the most devastating conditions we face? That question has shaped the career of Dr. Joshua Hare, a…
Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to…
As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research…
Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government…
Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched…
Manuel Guzman, President of CAS, a division of the American Chemical Society, outlines the organization’s vital role in scientific knowledge management and its commitment to accelerating breakthroughs in biomedical research.…
Regeneron has agreed to pay USD 256 million to acquire at-home DNA test maker 23andMe after the troubled firm declared bankruptcy. Through the buyout, Regeneron will acquire the data of…
2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the…
See our Cookie Privacy Policy Here
